RCUS Logo

Arcus Biosciences, Inc. (RCUS) 

NYSE
Market Cap
$1.42B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
1 of 960
Rank in Industry
1 of 550

Largest Insider Buys in Sector

RCUS Stock Price History Chart

RCUS Stock Performance

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in …

Insider Activity of Arcus Biosciences, Inc.

Over the last 12 months, insiders at Arcus Biosciences, Inc. have bought $320M and sold $2.75M worth of Arcus Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Arcus Biosciences, Inc. have bought $140.4M and sold $2.39M worth of stock each year.

Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $1.6B.

The last purchase of 15,238,095 shares for transaction amount of $320M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑01‑29.

List of Insider Buy and Sell Transactions, Arcus Biosciences, Inc.

2024-12-02SaleChief Accounting Officer
201
0.0002%
$15.32$3,079+7.31%
2024-08-13SaleChief Accounting Officer
1,357
0.0015%
$14.97$20,3140.00%
2024-03-27SaleChief Operating Officer
11,551
0.0123%
$17.55$202,720-11.04%
2024-03-18SaleChief Operating Officer
13,449
0.0154%
$17.92$240,941-5.37%
2024-02-27SalePresident
23,132
0.0255%
$20.10$464,953-18.56%
2024-02-27SaleChief Operating Officer
34,070
0.0376%
$20.11$685,148-18.56%
2024-02-26SalePresident
3,900
0.0044%
$20.06$78,234-16.38%
2024-02-26SaleChief Operating Officer
24,555
0.0276%
$20.07$492,819-16.38%
2024-01-29Purchase10 percent owner
15.24M
28.0689%
$21.00$320M+7.71%
2024-01-02SalePresident
6,975
0.0096%
$20.09$140,128-15.96%
2024-01-02SaleChief Financial Officer
2,004
0.0027%
$20.00$40,080-15.96%
2023-12-22SaleChief Operating Officer
21,521
0.028%
$17.76$382,213-9.92%
2023-12-01SaleChief Accounting Officer
282
0.0004%
$14.95$4,216+2.69%
2023-09-22SaleChief Operating Officer
21,369
0.0291%
$19.99$427,166-17.33%
2023-07-28SaleChief Operating Officer
45,000
0.0639%
$20.25$911,250-16.91%
2023-07-03SaleChief Accounting Officer
1,018
0.0014%
$20.41$20,777-17.18%
2023-06-28Purchase10 percent owner
1.01M
1.3257%
$19.26$19.45M-15.57%
2023-06-22SaleChief Operating Officer
12,437
0.0169%
$19.12$237,795-11.36%
2023-06-16SaleChief Operating Officer
12,563
0.017%
$19.35$243,094-11.87%
2023-06-07SaleChief Financial Officer
4,049
0.0054%
$20.04$81,142-15.94%

Insider Historical Profitability

4.73%
GILEAD SCIENCES, INC.10 percent owner
30061124
32.8495%
$15.5030<0.0001%
Jaen Juan C.President
1188233
1.2985%
$15.5089<0.0001%
Goeltz II Robert C.Chief Financial Officer
51831
0.0566%
$15.5015+33.11%
ROSEN TERRY JChief Executive Officer
242173
0.2646%
$15.50216<0.0001%
FALBERG KATHRYN Edirector
102106
0.1116%
$15.5070+8.71%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$186.92M10.899.9M-1.34%-$2.55M<0.01
State Street$92.6M5.394.9M+15.68%+$12.55M<0.01
The Vanguard Group$90.46M5.274.79M+2.36%+$2.09M<0.01
Fidelity Investments$90.23M5.264.78M+1.07%+$953,194.560.01
Woodline Partners LP$54.44M3.172.88M+178%+$34.86M0.47
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.